New combo therapy may simplify steroid diabetes care

NCT ID NCT07117240

ENROLLING_BY_INVITATION Disease control Sponsor: Medical University of Warsaw Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a combination of a GLP-1 drug (lixisenatide) plus long-acting insulin works better than standard intensive insulin therapy for people whose diabetes is caused by steroid medications. About 100 adults with conditions like asthma or arthritis who need long-term steroids will be enrolled. The goal is to see if the combo approach improves blood sugar control and reduces the need for extra insulin shots.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lixisenatide plus insulin glargine
What this could lead to: If this works, it could offer a simpler, more effective way to manage steroid-induced diabetes with fewer injections and better blood sugar control.
What could go wrong: This is a small, early-phase trial with only 100 participants, so results may not apply to everyone. The combination therapy may not prove superior or could cause side effects like nausea or low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus hyperglycemia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES STEROID INDUCED HYPERGLYCEMIA STEROID-INDUCED DIABETES

Contacts and locations

Locations

Warsaw Medical University

Warsaw, Warsaw, 02-097, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.